Open AccessTreatment and outcomes in anti-HMG-CoA reductase-associated immune-mediated necrotising myopathy. Comparative analysis of a single-centre cohort and published data
Author(s) -
Jan-Gerd Rademacher,
Stefanie Glaubitz,
Sabrina Zechel,
Manuela Oettler,
Björn Tampe,
Jens Schmidt,
Peter Korsten
Publication year - 2022
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/2ao5ze
Subject(s) - medicine , myopathy , azathioprine , statin , cohort , myalgia , interquartile range , creatine kinase , muscle weakness , gastroenterology , disease
Anti-hydroxy-methyl-glutaryl-coenzyme A reductase (HMGCR) antibody-associated myopathy was recognised as a new form of immune-mediated necrotising myopathy (IMNM) a decade ago. Due to the rarity of the disease, only limited data on clinical manifestations and therapeutic outcomes are available.